(Yahoo Finance) A number of hedge funds snapped up cancer drug maker Medivation’s stock during the second quarter possibly making for a nice win. On Monday, Medivation’s (MDVN) stock surged around 20% after pharma giant Pfizer (PFE) said it would acquire the biotech company in a $14 billion deal. The stock was last trading up $13.33 at $80.50 per share.
Medivation just made its debut on Goldman Sachs’ 50 stocks that “matter most” to hedge funds list, ranking No. 17 on the list.
